Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49

Journal of Nuclear Medicine

Volumn 38, Issue 4, 1997, Pages 512-516

  Leichner, Peter K ^a   Akabani, Gamal ^a   Colcher, David ^a   Harrison, Katherine A ^a   Hawkins, William G ^a   Eckblade, Miriam ^a   Baranowska Kortylewicz, Janina ^a   Augustine, Samuel C ^a   Wisecarver, James ^a   Tempero, Margaret A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

dosimetry; monoclonal antibody; radioimmunotherapy

Indexed keywords

IMMUNOGLOBULIN G; INDIUM 111; MONOCLONAL ANTIBODY CC49; YTTRIUM 90;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSE CALCULATION; DOSIMETRY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MATHEMATICAL COMPUTING; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ABSORPTION; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; GLYCOPROTEINS; HALF-LIFE; HUMANS; INDIUM RADIOISOTOPES; LIVER; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; SPLEEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 0030946346     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Esteban JM, Colcher D, Sugarbaker P, et al. Quantitative and qualitative aspect!, of radiolocalization in colon cancer patients of intravenously administered MAb B72..3. Int J Cancer 1987:39:50-59.
2. 1311-C< '49 in metastatic colon carcinoma. J Nucl Med !995;36:586-592.
3. 131I-CC49 in colorectal cancer. Cancer 1994:73:1057-1066.
4. Leichner PK. Yang N-C. Frenkel TL. et al. Dosimetry and treatment planning for Y-90 labeled antiferritin in hepatoma. Int J Radiât Oncol Biol Phys 1988:14:1033-1042.
5. Leichner PK. Koral KF, Jaszczak RJ, Green AJ, Chen GTY, Roeske JC. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys 1993:20:569-577.
6. Cheng R, Fordyce WA, Goecklercr WF, et al. Macrocyclic conjugates and their use as diagnostic and therapeutic agents. U.S. Patent 5,435,990: 1995.
7. Schott ME, Schlom J, Siler K, et al. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugatcs. Cancer 1994; 73(suppl):993-998.
8. Hawkins WG. Leichner PK, Yang N-C. The circular harmonic transform for SPE( T reconstruction and boundary conditions on the Fourier transform of the sinogram. IEEE Trans Med Ima 1988:7:135-148.
9. Hawkins WG, Yang N-C, Lcichner PK. Validation of the circular harmonic transfo.Tn (CHT) algorithm for quantitative SPECT. J Nucl Med 1991:32:141-150.
10. Leichner PK. Vriesendorp HM, Hawkins WG, et al. Quantitative SPECT for In-111 -labeled antibodies in the livers of beagle dogs. J Nucl Med 1991 ;32:1442- 1446
11. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. MIRD pamphlet no. 7. New York, NY: Society of Nuclear Medicine 1971:7-32.
12. Siegel JA. Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity lor radioimmunotherapy. Antibody Immunoconj Radiophar 1990:3:213-233.
13. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993:34:689-694.
14. Whitwell JR. Spiers FW. Calculated beta-ray dose factors for trabecular bone. Phss Med Biol 1976:21:16-38.
15. Breitz HB, Fisher DR, Weiden PL, et al. Dosimetry of Re-186-labeled monoclonal antibody: methods, prediction from Tc-99m-labelcd antibodies and results of Phase 1 trials. J Nucl Med 1993:34:908-917.
16. Breitz HB, Durham JS, Fisher DR. et al. Pharmacokinetics and normal orgin dosimetry following intraperitoneal Re-186-labeled monoclonal antibody. J Nucl Mcd 1995:36:754-761.
17. 131I distribution by gamma camera imaging. Eur J Nucl Med 1990:16:361-365.
18. Israel O, Iosilevsky G, Front D, et al. SPECT quantification of 1-131 concentration in phantoms and human tumors. J Nucl Med 1990;31:1945-1949.
19. Gilland DR. Jaszczak RJ, Gréer KL, Coleman RE. Quantitative SPECT reconstruction of 1-123 data. J Nucl Med 1991:32:527-533.
20. Gilland DR. Jaszczak RJ, Turkington TC, Gréer KL, Coleman RE. Quantitativ; SPECT imaging with In-Ill. IEEE Trans Nucl Sei 1991:32:761-766.
21. Stabin MG, Eckcrman KF, Ryman JC, Williams LE. Bremsstrahlung radiation dose i i Y-90 therapy applications..J Nucl Med 1994:35:1377-1380.
22. Snyder WS. Ford MR, Warner GG. Watson SB. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD pamphlet no. 11. New York: Society of Nuclear Medicine; 1975:144-145, 164 165.
23. Ingold J. Reed G. Kaplan H. Bagshaw M. Radiation hepatitis. Am J Roentgenol 1965:93:200-208.
24. Lewin K, Millis R. Human radiation hepatitis. Arch Path 1973:96:21-26.
25. Raoul JI. Bretagne JF, Cancanas JP, et al. Internal radiation therapy for hepatocellulacarcinoma: results of a French multicenter Phase III trial of transarterial injection o " 1-131 labeled lipiodol. Cancer 1992;69:346-352.
26. Gray BN. Burton MA, Kelleher D, Klemp P, Metz L. Tolerance of the liver to thi effects of Y-90 radiation. Int J Rad Oncol Biol Phys 1990; 18:619-623.
27. Andrews JC. Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B Hepatic radiocmbolisation with Y-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994:1637-1644.